Clinical Trials Logo
  1. Home
  2. Hepatobiliary Neoplasm
  3. NCT04959630

Immersive Virtual Reality Environment for Complex Cognitive Skills Curricular Training in Liver Surgery — LiVeRTrainer  

Hepatobiliary Neoplasm Clinical Trial

Official title:
Effectiveness of an Immersive Virtual Reality Environment on Curricular Training for Complex Cognitive Skills in Liver Surgery: A Multicentric Crossover Randomized Trial

Clinical Trial Summary

Investigators hypothesize that a virtual reality (VR) environment enhances general surgery residents' performance compared to Desktop Interface (DI)-based visualization of 3D models in decision making for patients with liver tumors. To determine this, a proficiency-based stepwise training curriculum for preoperative planning has been developed using both modalities. The overall objective of the curriculum is that by the end of the training program, residents would be able to formulate a treatment plan for patients with liver tumors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04959630
Study type Interventional
Source University Hospital, Ghent
Contact
Status Completed
Phase N/A
Start date September 1, 2020
Completion date June 15, 2021
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01020812 - Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma Phase 1/Phase 2
Completed NCT06049836 - Holographic Augmented Reality Versus Screen Visualisation of 3D Rendering Models for the Pre-operative Evaluation and Planning of Liver Resections N/A
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A
Recruiting NCT04010071 - Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors Phase 2
Recruiting NCT04709445 - Perfusion Rate Assessment by Near-infrared Fluorescence in Gastrointestinal Anastomoses N/A
Terminated NCT01151761 - PII of SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation Phase 2
Active, not recruiting NCT04501913 - Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
Withdrawn NCT03818997 - Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer Phase 2
Completed NCT04642664 - Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer Phase 2
Not yet recruiting NCT03760289 - DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer Phase 2
Terminated NCT00767234 - Permission to Collect Blood Over Time for Research N/A